pd-1 and ctla-4 blockade following progression on a pd-1 inhibitor in advanced melanoma
Published 2 years ago • 18 plays • Length 6:10Download video MP4
Download video MP3
Similar videos
-
2:35
beyond anti-pd-1 and anti-ctla-4 in melanoma
-
9:22
management of advanced melanoma after progression on anti-pd1 therapy
-
3:20
update in anti-ctla4 and anti-pd1 treatment in advanced melanoma
-
7:39
intratumoral tilsotolimod plus ipilimumab for advanced melanoma after pd-1 inhibitor progression
-
5:37
pd-1 inhibitor use in melanoma
-
9:02
pd1/ ctla4 : upfront or sequentially?
-
32:38
anti- pd1 treatment in advanced melanoma
-
7:37
combining immunotherapies: inhibiting the ctla-4 and pd-1 pathways
-
1:56
medi5752: novel pd-1/ctla-4 bispecific checkpoint inhibitor for advanced solid tumors
-
7:13
progression patterns in post-ipilimumab and anti-pd-1 in metastatic melanoma
-
1:54
two main pathways involved in immunotherapy pd 1 and ctla4
-
1:37
dr. adams on the utility of combination ctla-4 and pd-1 blockade in breast cancer
-
6:13
anti-pd-1 or anti-ctla-4 in first line therapy?
-
1:23
dr. agarwala on entinostat for patients with melanoma who progress on pd-1/pd-l1 blockade
-
10:14
neoantigen-targeted cd8 t-cell responses with pd-1 blockade therapy
-
2:19
combining ctla-4 agents with pd-1/pd-l1 agents in lung cancer
-
10:19
ipilimumab alone or in combination w anti-pd-1 therapy in pts w melanoma resistant to anti-pd1 mono
-
4:00
cancer immunotherapy - pd-1 and pd-l1